Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802974 | 0.89 | ADRB3 (0.43) | ADRB3ADRB1ADRB2MEN1POLB | |
| SCHEMBL6803252 | 0.89 | ADRB3 (0.40) | ADRB3ADRB1RORCMEN1POLB | |
| SCHEMBL6803258 | 0.89 | ADRB3 (0.40) | ADRB3ADRB1RORCMEN1POLB | |
| SCHEMBL6802972 | 0.87 | ADRB3 (0.40) | LTB4R2ADRB3ADRB1ADRB2BRS3 | |
| SCHEMBL6805800 | 0.84 | ADRB3 (0.44) | LTB4R2ADRB3ADRB1ADRB2BRS3 | |
| SCHEMBL6805795 | 0.84 | ADRB3 (0.44) | LTB4R2ADRB3ADRB1ADRB2BRS3 | |
| SCHEMBL6799393 | 0.83 | ADRB3 (0.56) | ADRB3ADRB1 | |
| SCHEMBL6801228 | 0.82 | ADRB3 (0.40) | ADRB3ADRB1LPAR1 | |
| SCHEMBL6801226 | 0.82 | ADRB3 (0.40) | ADRB3ADRB1LPAR1 | |
| SCHEMBL6540463 | 0.82 | PSEN1 (0.39) | ADRB3ADRB1MEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | LTB4R2 1688/4885ADRB3 150/4885ADRB1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.